Literature DB >> 28485504

Mechanistic Principles Behind Molecular Mechanism of Rifampicin Resistance in Mutant RNA Polymerase Beta Subunit of Mycobacterium tuberculosis.

Aditi Singh1,2, Sonam Grover3, Siddharth Sinha1, Mriganko Das2, Pallavi Somvanshi1, Abhinav Grover2.   

Abstract

Evolution of drug-resistant Mycobacterium strains threatens the TB treatment and control programs globally. Rifampicin (RIF) is an important first line antitubercular drug. Resistance to Rifampicin is caused mainly by mutations in its target RNA polymerase beta subunit protein (RpoB). RpoB contains a Rifampicin resistance determining region (RRDR) and has several potent sites for mutations. In this study, we have investigated mutations of a single site (H451) to eight different amino acids, involved in RIF resistance. Long-term molecular dynamics simulations were performed on wild type (WT) and mutant protein structures and various structural analysis were carried out to elucidate the dynamic behavior of WT and mutant forms. Essential dynamics uncovered the difference in conformational flexibility and collective modes of motions between WT and mutants. MMPBSA calculations and interaction pattern analysis revealed the binding site relocation in some mutants. This study presents an exhaustive analysis of RIF binding to the WT and mutant RpoB and clearly highlights structural mechanism for differences in stable binding of Rifampicin with WT than the mutant targets. J. Cell. Biochem. 118: 4594-4606, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  MECHANISM; RESISTANCE; RIFAMPICIN; RpoB; TB; TUBERCULOSIS

Mesh:

Substances:

Year:  2017        PMID: 28485504     DOI: 10.1002/jcb.26124

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

Review 1.  Rifamycin antibiotics and the mechanisms of their failure.

Authors:  Rebekah A Adams; Gabrielle Leon; Natalia M Miller; Saira P Reyes; Chantal H Thantrong; Alina M Thokkadam; Annabel S Lemma; Darshan M Sivaloganathan; Xuanqing Wan; Mark P Brynildsen
Journal:  J Antibiot (Tokyo)       Date:  2021-08-16       Impact factor: 2.649

2.  Role of Disputed Mutations in the rpoB Gene in Interpretation of Automated Liquid MGIT Culture Results for Rifampin Susceptibility Testing of Mycobacterium tuberculosis.

Authors:  Paolo Miotto; Andrea M Cabibbe; Emanuele Borroni; Massimo Degano; Daniela M Cirillo
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

3.  The PGRS Domain of Mycobacterium tuberculosis PE_PGRS Protein Rv0297 Is Involved in Endoplasmic Reticulum Stress-Mediated Apoptosis through Toll-Like Receptor 4.

Authors:  Sonam Grover; Tarina Sharma; Yadvir Singh; Sakshi Kohli; Manjunath P; Aditi Singh; Torsten Semmler; Lothar H Wieler; Karsten Tedin; Nasreen Z Ehtesham; Seyed E Hasnain
Journal:  MBio       Date:  2018-06-19       Impact factor: 7.867

4.  Structure-Based Screening of Non-β-Lactam Inhibitors against Class D β-Lactamases: An Approach of Docking and Molecular Dynamics.

Authors:  Divya Gupta; Aditi Singh; Pallavi Somvanshi; Ajeet Singh; Asad U Khan
Journal:  ACS Omega       Date:  2020-04-01

5.  The Structural Basis of Mycobacterium tuberculosis RpoB Drug-Resistant Clinical Mutations on Rifampicin Drug Binding.

Authors:  Arnold Amusengeri; Asifullah Khan; Özlem Tastan Bishop
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

Review 6.  Tuberculosis: Past, present and future of the treatment and drug discovery research.

Authors:  Ameya D Bendre; Peter J Peters; Janesh Kumar
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-05-27

7.  Topological and system-level protein interaction network (PIN) analyses to deduce molecular mechanism of curcumin.

Authors:  Anupam Dhasmana; Swati Uniyal; Vivek Kumar Kashyap; Pallavi Somvanshi; Meenu Gupta; Uma Bhardwaj; Meena Jaggi; Murali M Yallapu; Shafiul Haque; Subhash C Chauhan
Journal:  Sci Rep       Date:  2020-07-21       Impact factor: 4.379

8.  Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis.

Authors:  Bharati Pandey; Sonam Grover; Jagdeep Kaur; Abhinav Grover
Journal:  Sci Rep       Date:  2019-09-20       Impact factor: 4.379

9.  Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.

Authors:  Nabeela Farhat; Asad U Khan
Journal:  J Mol Model       Date:  2021-10-02       Impact factor: 1.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.